HDAC (Histone deacetylases) are a class of enzymes that remove acetyl groups (O=C-CH3) from an ε-N-acetyl lysine amino acid on ahistone, allowing the histones to wrap the DNA more tightly.This is significant because DNA is wrapped around histones and that acetylation and de-acetylation control how DNA is expressed. In contrast to histone acetyltransferase, it acts differently. Since non-histone proteins are also among their targets, HDAC proteins are now also referred to as lysine deacetylases (KDAC) in order to better reflect their mode of action. The histone deacetylases are members of the ancient protein superfamily known as the histone deacetylase superfamily, along with the acetylpolyamine amidohydrolases and the acetoin utilization proteins.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V4087 | UF010 | 537672-41-6 | UF010 (UF-010; UF 010) is a novel, potent and selective class I HDAC inhibitor with potential anticancer activities. |
|
V97450 | Acefylline piperazine | 18833-13-1 | Acetylphylline piperazine is a xanthine derivative and adenosine receptor antagonist. |
|
V3772 | ACY-775 | 1375466-18-4 | ACY-775, anovel pyrimidine hydroxyl amide small molecule, is a brain bioavailable, highly potent and isoform-selective inhibitor of HDAC6 with IC50of 7.5 nM. |
|
V2346 | AES-350 | 847249-57-4 | AES-350 is a potent orally bioactive HDAC6 inhibitor (antagonist) with IC50 and Ki of 0.0244 μM and 0.035 μM, respectively. |
|
V89054 | ALK/HDAC-IN-1 | ALK/HDAC-IN-1 is a dual inhibitor of ALK and HDAC6 with IC50 of 16 nM and 1.03 μM, respectively. | |
|
V88674 | AW01178 | 651293-70-8 | AW01178 is a class I HDAC inhibitor. |
|
V85459 | BATCP | 787549-23-9 | |
|
V9315 | BRD6688 | 1404562-17-9 | BRD6688 (BRD-6688; BRD 6688) is a novel and potent HDAC1/2/3 inhibitor with IC50s of 21 nM, 100 nM, and 11.48 μM, respectively. |
|
V84303 | CM-1758 | 2256079-39-5 | |
|
V18790 | Crebinostat | 1092061-61-4 | Crebinostat is a novel and potent HDAC (histone deacetylase) inhibitor with anticancer and neuroprotective effects. |
|
V87366 | CYP17A1/HDAC6-IN-1 | CYP17A1/HDAC6-IN-1 (compound 12) is a potent inhibitor of CYP17A1 and HDAC6 with IC50 of 0.284μM and 0.6015 μM respectively. | |
|
V88667 | DL-Sulforaphane N-acetyl-L-cysteine | 334829-66-2 | DL-Sulforaphane N-acetyl-L-cysteine (SFN-NAC) is an orally active HDAC inhibitor and a metabolite of sulforaphane with a longer half-life and better blood-brain barrier permeability. |
|
V88739 | DLC-50 | 2928537-98-6 | DLC-50 is a dual inhibitor of PARP-1 and HDAC-1 with IC50 of 1.2 nM and 31 nM, respectively. |
|
V96662 | DNMT1/HDAC-IN-1 | DNMT1/HDAC-IN-1 (Compound (R)-23a) is a DNMT1/HDAC dual inhibitor (HDAC1: IC50=0.05 μM), HDAC1 is a major HDAC isoform that interacts with DNMT1 in multiple protein complexes to silence the transcription of TSGs. | |
|
V99825 | F-SAHA | 149648-08-8 | F-SAHA is a HDAC inhibitor (HDACi), and its 18F-labeled derivatives can be used for tumor imaging studies. |
|
V93364 | FITC-SAHA | 1160823-10-8 | FITC-SAHA is a conjugate of SAHA and fluorescein. |
|
V96816 | FLT3/HDAC-IN-2 | FLT3/HDAC-IN-2 (Compound 25h) is a FLT3/HDAC dual inhibitor. | |
|
V31524 | FT895 | 2225728-57-2 | FT895 is a potent and specific HDAC11 inhibitor (antagonist) with IC50 of 3 nM. |
|
V3844 | Givinostat HCl | 199657-29-9 | Givinostat (ITF-2357 hydrochloride)is a potent andorally bioactive HDAC inhibitor with potential anti-inflammatory, anti-angiogenic, and anticancer activities. |
|
V87896 | GSK-3β/HDAC-IN-1 | GSK-3β/HDAC-IN-1 (Compd 4) is a first-in-class non-ATP-competitive glycogen synthase kinase 3β/histone deacetylase (GSK-3β/HDACs) inhibitor that penetrates the blood-brain barrier, with IC50 of 0.142, 0.03, and 0.045 μM for GSK-3β, HDAC2, and HDAC6, respectively |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
